Chengxia Shu

Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer

Xiaoyu Chen, Chengxia Shu, Wenqiang Li et al. · Journal of Medicinal Chemistry · 2022 · 21 citations · Full text

Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers

Qiangqiang Hou, Wenhua Jiang, Wenqiang Li et al. · Journal of Medicinal Chemistry · 2023 · 12 citations · Full text

Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer

Wenhua Jiang, Xiaohui Wang, Chengxia Shu et al. · Bioorganic Chemistry · 2021 · 11 citations